Trial Profile
A 3-week, Multi-center, Open-label, Randomized, Active-control, Parallel-group Study to Compare Effects of Nateglinide and Acarbose on Postprandial Glucose Fluctuation in Chinese Drug-naive Patients Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Nateglinide (Primary) ; Acarbose
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ENERGY 2
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Dec 2009 New trial record